Drugs / SHR-2005
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06108492 | Nov 2023 → Dec 2026 expected | urinary bladder carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06588179 | Oct 2024 → Oct 2027 expected | non-invasive bladder urothelial carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06108492 ↗ |
| Route | Other | “SHR-2005, instillation” NCT06588179 ↗ |